A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models
Elliott RJR. et al, (2024)
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer Med, 13
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Kent D. et al, (2024), Hepatology
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nat Commun, 15
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R. et al, (2024), J Immunother Cancer, 12
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages.
Navarro-Guerrero E. et al, (2024), STAR Protoc, 5
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Bešević J. et al, (2023), J Epidemiol Community Health, 78, 105 - 108
Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia.
Fayed HS. et al, (2023), Int J Mol Sci, 24
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells.
Athanasiadis P. et al, (2023), iScience, 26
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Buckell J. et al, (2023), Sci Rep, 13
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J. et al, (2023), Nat Commun, 14
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)